News Brilique boosted by NICE’s long-term prevention recommendati... Recommendation will add to growth trajectory
News AZ's key drug Brilique fails in stroke trial Disappointment for AstraZeneca and key growth driver
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
